Niagen Bioscience Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NAGE?
Source: seekingalpha
- Significant Revenue Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with full-year revenue reaching $129.4 million, representing a 30% growth, indicating strong market performance and sustained growth potential.
- Net Income Improvement: The net income for Q4 was $4.1 million, translating to $0.05 per share, while the annual net income reached $17.4 million, a 102% increase from 2024, reflecting the company's success in operational efficiency and cost control.
- New Product Strategy: The company plans to launch Niagen Plus at-home injection kits in the first half of 2026 and aims to partner with other telehealth providers, showcasing its proactive approach in innovative products and services.
- Legal Challenges and Market Outlook: Niagen Bioscience has initiated litigation in federal court in Washington, D.C. against the FDA's reversal on NMN's supplement status, with management expressing confidence in the case, while projecting revenue growth of 10% to 15% for 2026, reflecting a cautious stance towards competitive and regulatory risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.870
Low
12.00
Averages
16.33
High
23.00
Current: 4.870
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Niagen Bioscience Q4 2025 Earnings Highlights
- Significant Revenue Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with full-year revenue reaching $129.4 million, representing a 30% growth, indicating strong market performance and sustained growth potential.
- Net Income Improvement: The net income for Q4 was $4.1 million, translating to $0.05 per share, while the annual net income reached $17.4 million, a 102% increase from 2024, reflecting the company's success in operational efficiency and cost control.
- New Product Strategy: The company plans to launch Niagen Plus at-home injection kits in the first half of 2026 and aims to partner with other telehealth providers, showcasing its proactive approach in innovative products and services.
- Legal Challenges and Market Outlook: Niagen Bioscience has initiated litigation in federal court in Washington, D.C. against the FDA's reversal on NMN's supplement status, with management expressing confidence in the case, while projecting revenue growth of 10% to 15% for 2026, reflecting a cautious stance towards competitive and regulatory risks.
See More
U.S. and Ecuador Jointly Target Drug Traffickers
- Joint Military Operation: The U.S. and Ecuador conducted a joint military operation on Tuesday targeting criminal gangs designated as foreign terrorist organizations, such as Los Choneros and Los Lobos, marking a new phase in Washington's campaign against drug trafficking in Latin America.
- Deepening Strategic Cooperation: Ecuadorian President Noboa stated that the country is entering a new phase in its fight against organized crime, emphasizing the continuation of joint missions with international partners to aggressively tackle narcotrafficking and illegal mining threats.
- Enhanced Technical Support: U.S. support includes funding for surveillance technology and drones, as well as the temporary deployment of Air Force personnel to Ecuador's Manta air base to assist with anti-drug missions, highlighting the importance of Ecuador as a key partner in this effort.
- Response to Rising Violence: Despite capturing two major gang leaders in the past year, violence continues to escalate in Ecuador, prompting the government to implement aggressive security measures, including troop deployments and expanded emergency powers, to address the growing drug-related violence.
See More
Niagen Bioscience Reports Strong 2025 Earnings Performance
- Financial Performance Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with total net revenue for the year reaching $129.4 million, reflecting a robust 30% growth in the NAD market.
- Cash Flow and Debt-Free Status: By the end of 2025, the company had $64.8 million in cash and no debt, enhancing financial flexibility and providing a solid foundation for future investments and expansion.
- Scientific Research Leadership: Niagen continues to lead in NAD science, with 29 studies on nicotinamide riboside published, including 8 clinical studies, reinforcing its position as the gold standard for NAD precursors.
- New Products and Market Expansion: The upcoming launch of Niagen Plus injectable formulations is expected to expand into over 1,200 health clinics through its telehealth platform and partnerships, driving further penetration into the beauty and health markets.
See More
Niagen Bioscience Reports Strong Financial Growth
- Financial Performance Breakthrough: Niagen Bioscience reported net sales of $129.4 million for 2025, marking a 30% year-over-year increase, which not only hit the top end of its guidance but also exceeded Wall Street expectations, showcasing its strong performance in the anti-aging market.
- Profit Doubling: The company's net income doubled from $8.6 million to $17.7 million, reflecting sustained demand for its products, while ending the year with $64.8 million in cash and no debt, enhancing its financial flexibility for future expansions.
- Market Expansion Plans: CEO Rob Fried indicated that the company is actively seeking acquisition targets and plans to establish partnerships in orphan diseases within the next 18 months, demonstrating its strategic positioning in new markets and product lines.
- Cautious Future Outlook: Although 2026 revenue is projected at $145 million, indicating approximately 15% growth, Fried noted that increased competition necessitates a conservative outlook, reflecting the complexities of the market environment.
See More
Niagen Bioscience Q4 Earnings Exceed Expectations
- Strong Performance: Niagen Bioscience reported a Q4 GAAP EPS of $0.05, beating estimates by $0.03, with revenue of $33.84 million reflecting a 16.3% year-over-year increase, surpassing expectations by $2.14 million, indicating robust performance in the supplement market.
- 2026 Outlook: The company anticipates net sales growth between 10-15% year-over-year, excluding 2025 revenue from the Analytical Reference Standards and Services segment, primarily driven by e-commerce and new strategic partnerships, showcasing confidence in future growth.
- Gross Margin Improvement: There was a slight year-over-year improvement in gross margin, attributed to better inventory costs and product mix, demonstrating effective strategies in cost control and product optimization.
- Expense Structure Adjustments: While sales and marketing expenses increased in absolute terms, they remained stable as a percentage of sales, with R&D expenses also rising, reflecting ongoing investments in pharmaceutical development and external research to support new market expansions.
See More
Niagen Bioscience to Announce Q4 Earnings on March 4
- Earnings Announcement Schedule: Niagen Bioscience is set to release its Q4 earnings on March 4 after market close, with a consensus EPS estimate of $0.02, reflecting a significant year-over-year decline of 77.8%, indicating profitability challenges for the company.
- Revenue Forecast Analysis: The anticipated revenue for Q4 is $31.7 million, representing an 8.9% year-over-year increase, which, while modest, suggests that the company is maintaining a certain market share in a highly competitive supplement market.
- Patent Acquisition Update: Niagen Bioscience has recently acquired key Nicotinamide Riboside patents, a strategic move aimed at enhancing its product line's competitiveness and potentially laying the groundwork for future revenue growth.
- Market Environment Challenges: Amidst intensifying competition in the supplement market, Niagen Bioscience emphasizes the importance of maintaining discipline in product development and marketing to navigate industry challenges and enhance brand influence.
See More
Niagen Bioscience Q4 2025 Earnings Highlights
- Significant Revenue Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with full-year revenue reaching $129.4 million, representing a 30% growth, indicating strong market performance and sustained growth potential.
- Net Income Improvement: The net income for Q4 was $4.1 million, translating to $0.05 per share, while the annual net income reached $17.4 million, a 102% increase from 2024, reflecting the company's success in operational efficiency and cost control.
- New Product Strategy: The company plans to launch Niagen Plus at-home injection kits in the first half of 2026 and aims to partner with other telehealth providers, showcasing its proactive approach in innovative products and services.
- Legal Challenges and Market Outlook: Niagen Bioscience has initiated litigation in federal court in Washington, D.C. against the FDA's reversal on NMN's supplement status, with management expressing confidence in the case, while projecting revenue growth of 10% to 15% for 2026, reflecting a cautious stance towards competitive and regulatory risks.
See More
U.S. and Ecuador Jointly Target Drug Traffickers
- Joint Military Operation: The U.S. and Ecuador conducted a joint military operation on Tuesday targeting criminal gangs designated as foreign terrorist organizations, such as Los Choneros and Los Lobos, marking a new phase in Washington's campaign against drug trafficking in Latin America.
- Deepening Strategic Cooperation: Ecuadorian President Noboa stated that the country is entering a new phase in its fight against organized crime, emphasizing the continuation of joint missions with international partners to aggressively tackle narcotrafficking and illegal mining threats.
- Enhanced Technical Support: U.S. support includes funding for surveillance technology and drones, as well as the temporary deployment of Air Force personnel to Ecuador's Manta air base to assist with anti-drug missions, highlighting the importance of Ecuador as a key partner in this effort.
- Response to Rising Violence: Despite capturing two major gang leaders in the past year, violence continues to escalate in Ecuador, prompting the government to implement aggressive security measures, including troop deployments and expanded emergency powers, to address the growing drug-related violence.
See More
Niagen Bioscience Reports Strong 2025 Earnings Performance
- Financial Performance Growth: In Q4 2025, Niagen Bioscience reported revenue of $33.8 million, a 16% year-over-year increase, with total net revenue for the year reaching $129.4 million, reflecting a robust 30% growth in the NAD market.
- Cash Flow and Debt-Free Status: By the end of 2025, the company had $64.8 million in cash and no debt, enhancing financial flexibility and providing a solid foundation for future investments and expansion.
- Scientific Research Leadership: Niagen continues to lead in NAD science, with 29 studies on nicotinamide riboside published, including 8 clinical studies, reinforcing its position as the gold standard for NAD precursors.
- New Products and Market Expansion: The upcoming launch of Niagen Plus injectable formulations is expected to expand into over 1,200 health clinics through its telehealth platform and partnerships, driving further penetration into the beauty and health markets.
See More
Niagen Bioscience Reports Strong Financial Growth
- Financial Performance Breakthrough: Niagen Bioscience reported net sales of $129.4 million for 2025, marking a 30% year-over-year increase, which not only hit the top end of its guidance but also exceeded Wall Street expectations, showcasing its strong performance in the anti-aging market.
- Profit Doubling: The company's net income doubled from $8.6 million to $17.7 million, reflecting sustained demand for its products, while ending the year with $64.8 million in cash and no debt, enhancing its financial flexibility for future expansions.
- Market Expansion Plans: CEO Rob Fried indicated that the company is actively seeking acquisition targets and plans to establish partnerships in orphan diseases within the next 18 months, demonstrating its strategic positioning in new markets and product lines.
- Cautious Future Outlook: Although 2026 revenue is projected at $145 million, indicating approximately 15% growth, Fried noted that increased competition necessitates a conservative outlook, reflecting the complexities of the market environment.
See More
Niagen Bioscience Q4 Earnings Exceed Expectations
- Strong Performance: Niagen Bioscience reported a Q4 GAAP EPS of $0.05, beating estimates by $0.03, with revenue of $33.84 million reflecting a 16.3% year-over-year increase, surpassing expectations by $2.14 million, indicating robust performance in the supplement market.
- 2026 Outlook: The company anticipates net sales growth between 10-15% year-over-year, excluding 2025 revenue from the Analytical Reference Standards and Services segment, primarily driven by e-commerce and new strategic partnerships, showcasing confidence in future growth.
- Gross Margin Improvement: There was a slight year-over-year improvement in gross margin, attributed to better inventory costs and product mix, demonstrating effective strategies in cost control and product optimization.
- Expense Structure Adjustments: While sales and marketing expenses increased in absolute terms, they remained stable as a percentage of sales, with R&D expenses also rising, reflecting ongoing investments in pharmaceutical development and external research to support new market expansions.
See More
Niagen Bioscience to Announce Q4 Earnings on March 4
- Earnings Announcement Schedule: Niagen Bioscience is set to release its Q4 earnings on March 4 after market close, with a consensus EPS estimate of $0.02, reflecting a significant year-over-year decline of 77.8%, indicating profitability challenges for the company.
- Revenue Forecast Analysis: The anticipated revenue for Q4 is $31.7 million, representing an 8.9% year-over-year increase, which, while modest, suggests that the company is maintaining a certain market share in a highly competitive supplement market.
- Patent Acquisition Update: Niagen Bioscience has recently acquired key Nicotinamide Riboside patents, a strategic move aimed at enhancing its product line's competitiveness and potentially laying the groundwork for future revenue growth.
- Market Environment Challenges: Amidst intensifying competition in the supplement market, Niagen Bioscience emphasizes the importance of maintaining discipline in product development and marketing to navigate industry challenges and enhance brand influence.
See More
